Polypeptide With Localisation/Targeting Motif TRIZ Cases

Targeted insertion into the EEF1A1 locus prevents promoter silencing and ensures stable expression in differentiated T-cells.

An engineered NK cell uses a cotinine-specific CAR to target tumors, reducing toxicity and production costs.

A recombinant NLS-Eomes-PTD polypeptide enters natural killer cells to restore cytotoxic function and cytokine secretion.

Conjugating growth hormone with chorionic gonadotropin carboxy-terminal peptides extends serum circulation time.

Hydrocarbon-stapled polypeptides targeting the Syt2-SNAP-23 complex reduce stimulated mucin hypersecretion without affecting baseline secretion mechanisms.

Immunoresponsive cells express modified pro-cytokines cleaved by specific proteases to activate cytokine activity.

Engineered T cells evade host immune attack by eliminating endogenous T cell receptor genes.

NFAT-responsive reporter constructs replace inefficient manual assays with automated fluorescent signals to accelerate high-throughput CAR therapy development.

A split Gal4 biosensor labels cells reversing apoptosis to track anastasis events.

A closed system integrates activation, transduction, and expansion of T cells and NK cells within a single chamber using lentiviral particles.

Chimeric Tim receptors costimulate T cells to enhance proliferation and cytotoxic activity while reducing exhaustion from prolonged antigen exposure.

Recombinant yeast expressing heterologous glucoamylase eliminates exogenous enzyme costs by enabling internal starch hydrolysis.

Chimeric OspA polypeptides merge immunogenic regions from multiple Borrelia serotypes into a single antigen construct.

Tethering donor DNA via a consensus sequence bridges the gap between low HDR efficiency and NHEJ imprecision, enabling high-fidelity gene modification.

A fusion protein combines PPR motifs with functional domains to guide ribosomes and promote translation of target mRNA sequences.

A nucleic acid expression vector uses a T7 promoter and Gaussia luciferase signal peptide to drive protein secretion in mammalian cells.

A P3L polypeptide binds expanded CAG-repeat RNA with high affinity to suppress toxicity.

Segmenting the spike protein into RBD and NTD antigens accelerates vaccine development while ensuring safety.

Measuring inflammation-related soluble factors in patient serum to predict chimeric antigen receptor T cell therapy responsiveness.

Chimeric antigen receptor dendritic cells recognize tumor antigens and differentiate from monocytes to activate immune responses.

Replacing chemical inducers, a light-responsive DNA-binding protein enables rapid gene expression control through optical activation.

A biomolecular interaction detection method uses a translocation module to move constructs within cells for real-time monitoring.

Fusion peptides bind ATF3 to reduce inflammatory cytokine production, addressing the lack of effective inhibitors.

Engineered CAR T-cells with FLT3-binding domains selectively destroy acute myeloid leukemia cells while sparing healthy tissue from systemic toxicity.

A CP2c-targeting peptide conjugated with unsaturated fatty acids enhances in vivo stability and cell penetration.

Segmenting Cas9 into two polypeptides joined by a chemical inducer resolves the trade-off between enzyme activity control and guide RNA complexity.

Segmented CAAR constructs replace broad immunosuppression by specifically binding and killing MuSK autoantibody-producing B cells.

Bi-specific CAR-T cells target CD83 and IL-6R to eliminate alloreactive donor T cells.

Covalent cellulosomes link catalytic modules via spacers to boost enzymatic activity while simplifying recombinant expression.

A mitochondrial localization amino acid sequence directs a base editor fusion protein to modify mitochondrial DNA.

A chimeric protein expression system directs target proteins to the secretory pathway using non-mammalian signal peptides.

A recombinant polypeptide conjugates the cell-penetrating peptide DPV3 with an Hsp40-J domain to facilitate target agent entry into cells.

Inhibitory chimeric antigen receptors use ITSM motifs to attenuate T-cell activation and prevent off-target activity.

Modified CAR-T cells overcome tumor immune suppression by altering metabolic pathways to improve anti-tumor efficacy.

Chimeric Notch receptors incorporate a synthetic zinc finger transcriptional effector module to modulate gene expression in ligand-dependent cellular systems.

Novel CAR design incorporates intracellular NK activating receptor regions to enhance T cell activation and persistence.

Engineered TIR variants modulate translation speed to coordinate protein folding with secretion pathways, boosting antibody titers.

Immunostimulatory peptides fused to multimerizing domains assemble into complexes that activate antigen-presenting cells.

Multi-target CAR T-cells co-express anti-CD72 receptors to overcome antigen escape and prevent relapse in B cell lymphomas.

Reference unit calculations standardize CAR T cell dosing to reduce severe neurotoxicity risks while maintaining therapeutic efficacy.

Ex vivo expanded virally educated T cells combined with IL-15 agonists reverse viral latency and alleviate persistent Long Covid symptoms.

Engineered chimeric antigen receptors redirect T cells to eliminate prostate cancer cells while sparing healthy tissue.

ACAT inhibition eliminates cccDNA reservoirs, restoring immune function for sustained off-treatment viral suppression.

Optimized 5' and 3' untranslated regions enhance mRNA stability, overcoming rapid degradation in short-lived myeloid cells.

Chimeric antigen receptors incorporate a GITR intracellular domain to reduce cytokine release syndrome and off-target cytotoxicity.

TAT-calmodulin adaptors enable safe protein delivery into cells, simplifying purification and reducing hazards associated with direct conjugation methods.